Approaching a new era for hepatitis C virus therapy: Inhibitors of the NS3-4A serine protease and the NS5B RNA-dependent RNA polymerase

Antiviral Research

Volumn 58, Issue 1, 2003, Pages 1-16

  De Francesco, Raffaele ^a   Tomei, Licia ^a   Altamura, Sergio ^a   Summa, Vincenzo ^a   Migliaccio, Giovanni ^a  

^a IRBM   (Italy)

Author keywords

HCV; Hepatitis C; NNI; Nucleoside analogue; Protease inhibitor; Pyrophosphate mimic; RdRp; RNA dependent RNA polymerase

Indexed keywords

2 OXOACID; ALDEHYDE DERIVATIVE; AMIDE; ANTIVIRUS AGENT; AZAPEPTIDE; BENZOTHIADIAZINE DERIVATIVE; BETA DEXTRO 2' METHYLRIBOFURANOSYLGUANOSINE; BORONIC ACID DERIVATIVE; CILUPREVIR; DEXTRO RIBAVIRIN; DIHYDROXYPYRIMIDINE CARBOXYLATE; DIKETOACID; FOSCARNET; HEXAPEPTIDE; IMIDAZOLE DERIVATIVE; JTK 003; LACTAM DERIVATIVE; MACROGOL 400; NS3 4A SERINE PROTEASE; NS5B RNA DIRECTED RNA POLYMERASE; NUCLEOSIDE DERIVATIVE; NUCLEOTIDYLTRANSFERASE INHIBITOR; PHOSPHONOACETIC ACID; PYROPHOSPHORIC ACID DERIVATIVE; RIBAVIRIN DERIVATIVE; RNA DIRECTED RNA POLYMERASE; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; VIRUS PROTEIN;

AMINO TERMINAL SEQUENCE; ANTIVIRAL ACTIVITY; BIOASSAY; CARBOXY TERMINAL SEQUENCE; CLINICAL TRIAL; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG DESIGN; DRUG EFFECT; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SAFETY; DRUG SCREENING; DRUG TARGETING; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME SUBSTRATE; GENE REPLICATION; GENE STRUCTURE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INHIBITION KINETICS; MAXIMUM TOLERATED DOSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEINASE INHIBITION; REVIEW; SEQUENCE ANALYSIS; STRUCTURE ANALYSIS; VIRUS GENOME;

ANIMALIA; HEPATITIS C VIRUS;

EID: 0037367315     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(03)00028-7     Document Type: Review

References (143)

1. Ago H., Adachi T., Yoshida A., Yamamoto M., Habuka N., Yatsunami K., Miyano M. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Struct. Fold. Des. 7:1999;1417-1426.
2. Al R.H., Xie Y., Wang Y., Hagedorn C.H. Expression of recombinant hepatitis C virus non-structural protein 5B in Escherichia coli. Virus Res. 53:1998;141-149.
3. Altamura, S., Tomei, L., Koch, J.O., Neuner, P.J.S., Summa, V., 2000. Diketoacid-derivatives as inhibitors of viral polymerases. Int. Patent Appl. WO 00/06529. Istituto di Ricerche di Biologia Molecolare P. Angeletti, SpA.
4. Barbato G., Cicero D.O., Nardi M.C., Steinkuhler C., Cortese R., De Francesco R., Bazzo R. The solution structure of the N-terminal proteinase domain of the hepatitis C virus (HCV) NS3 protein provides new insights into its activation and catalytic mechanism. J. Mol. Biol. 289:1999;371-384.
5. Bartenschlager R. Innovation: hepatitis C virus replicons: potential role for drug development. Nat. Rev. Drug Discov. 1:2002;911-916.
6. Bartenschlager R., Lohmann V. Novel cell culture systems for the hepatitis C virus. Antivir. Res. 52:2001;1-17.
7. Bartenschlager R., Ahlborn-Laake L., Mous J., Jacobsen H. Nonstructural protein 3 of the hepatitis C virus encodes a serine-type proteinase required for cleavage at the NS3/4 and NS4/5 junctions. J. Virol. 67:1993;3835-3844.
8. Bartenschlager R., Ahlborn-Laake L., Yasargil K., Mous J., Jacobsen H. Substrate determinants for cleavage in cis and in trans by the hepatitis C virus NS3 proteinase. J. Virol. 69:1995;198-205.
9. Beaulieu P.-L., Llinas-Brunet M. Therapies for hepatitis C infection: targeting the non-structural proteins of HCV. Curr. Med. Chem. 1:2002;163-176.
10. Beaulieu, P.-L., Fazal, G., Gillard, J., Kukolj, G., Austel, V., 2002. Viral polymerase inhibitors. Int. Patent Appl. WO 02/04425. Boehringer Ingelheim (Canada) Ltd.
11. Behrens S.E., Tomei L., De Francesco R. Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus. EMBO J. 15:1996;12-22.
12. Benhamou, Y., Hinrichsen, H., Sentjens, R., Reiser, M., Manns, M.P., Forns, X., Avendano, C., Crönlein, J., Nehmiz, G., Steinmann, G., 2002. Safety, tolerability and antiviral effect of BILN 2061, a novel HCV serine protease inhibitor, after oral treatment over 2 days in patients with chronic hepatitis C, genotype 1, with advanced liver fibrosis. Hepatology 34 (Suppl. 4, Pt. 2), Abst. 463.
13. Bennett J.M., Campbell A.D., Campbell A.J., Carr M.G., Dunsdon R.M., Greening J.R., Hurst D.N., Jennings N.S., Jones P.S., Jordan S., Kay P.B., O'Brien M.A., King-Underwood J., Raynham T.M., Wilkinson C.S., Wilkinson T.C., Wilson F.X. The identification of alpha-ketoamides as potent inhibitors of hepatitis C virus NS3-4A proteinase. Bioorg. Med. Chem. Lett. 11:2001;355-357.
14. Blight K.J., Kolykhalov A.A., Rice C.M. Efficient initiation of HCV RNA replication in cell culture. Science. 290:2000;1972-1974.
15. Blight K.J., McKeating J.A., Rice C.M. Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J. Virol. 76:2002;13001-13014.
16. Bressanelli S., Tomei L., Roussel A., Incitti I., Vitale R.L., Mathieu M., De Francesco R., Rey F.A. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Proc. Natl. Acad. Sci. U.S.A. 96:1999;13034-13039.
17. Bressanelli S., Tomei L., Rey F.A., De Francesco R. Structural analysis of the hepatitis C virus RNA polymerase in complex with ribonucleotides. J. Virol. 76:2002;3482-3492.
18. Butcher S.J., Grimes J.M., Makeyev E.V., Bamford D.H., Stuart D.I. A mechanism for initiating RNA-dependent RNA polymerization. Nature. 410:2001;235-240.
19. Chander G., Sulkowski M.S., Jenckes M.W., Torbenson M.S., Bass H.F. Treatment of chronic hepatitis C: a systematic review. Hepatology. 36:2002;S135-S144.
20. Choo Q.L., Kuo G., Weiner A.J., Overby L.R., Bradley D.W., Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 244:1989;359-362.
21. Colarusso S., Gerlach B., Koch U., Muraglia E., Conte I., Stansfield I., Matassa V.G., Narjes F. Evolution, synthesis and SAR of tripeptide alpha-ketoacid inhibitors of the hepatitis C virus NS3/NS4A serine protease. Bioorg. Med. Chem. Lett. 12:2002a;705-708.
22. Colarusso, S., Koch, U., Gerlach, B., Steinkuhler, C., De Francesco, R., Altamura, S., Matassa, V.G., Narjes, F., 2002b. Phenetyl amides as novel non-covalent inhibitors of hepatitis C virus NS3/4A protease: discovery, initial SAR and molecular modeling. J. Med. Chem., in press.
23. Crotty S., Maag D., Arnold J.J., Zhong W., Lau J.Y., Hong Z., Andino R., Cameron C.E. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat. Med. 6:2000;1375-1379.
24. Crumpacker C.S. Mechanism of action of Foscarnet against viral polymerases. Am. J. Med. 92:1992;3S-7S.
25. De Clercq E. 2001 ASPET Otto Krayer Award lecture. Molecular targets for antiviral agents. J. Pharmacol. Exp. Ther. 297:2001a;1-10.
26. De Clercq E. Antiviral drugs: current state of the art. J. Clin. Virol. 22:2001b;73-89.
27. De Francesco R., Steinkuhler C. Structure and function of the hepatitis C virus NS3-NS4A serine proteinase. Curr. Top. Microbiol. Immunol. 242:2000;149-169.
28. De Francesco R., Behrens S.E., Tomei L., Altamura S., Jiricny J. RNA-dependent RNA polymerase of hepatitis C virus. Methods Enzymol. 275:1996a;58-67.
29. De Francesco R., Urbani A., Nardi M.C., Tomei L., Steinkuhler C., Tramontano A. A zinc binding site in viral serine proteinases. Biochemistry. 35:1996b;13282-71328.
30. De Francesco R., Pessi A., Steinkuhler C. The hepatitis C virus NS3 proteinase: structure and function of a zinc-containing serine proteinase. Antivir. Ther. 3(Suppl. 3):1998;99-109.
31. De Francesco R., Pessi A., Steinkuhler C. Mechanisms of hepatitis C virus NS3 proteinase inhibitors. J. Viral Hepat. 6(Suppl. 1):1999;23-30.
32. Dhanak, D., Kaura, A., Shaw, A., 2001. Novel anti-infectives. Int. Patent Appl. WO 01/85172. Smithkline Beechham Corporation, Int.
33. Di Bisceglie A.M., Hoofnagle J.H. Optimal therapy of hepatitis C. Hepatology. 36(Suppl. 1):2002;S121-S127.
34. Ede N.J., Eagle S.N., Wickham G., Bray A.M., Warne B., Shoemaker K., Rosenberg S. Solid phase synthesis of peptide aldehyde protease inhibitors. Probing the proteolytic sites of hepatitis C virus polyprotein. J. Pept. Sci. 6:2000;11-18.
35. Edwards P.D., Bernstein P.R. Synthetic inhibitors of elastase. Med. Res. Rev. 14:1994;127-194.
36. Ferrari E., Wright-Minogue J., Fang J.W., Baroudy B.M., Lau J.Y., Hong Z. Characterization of soluble hepatitis C virus RNA-dependent RNA polymerase expressed in Escherichia coli. J. Virol. 73:1999;1649-1654.
37. Fischmann T.O., Weber P.C. Peptidic inhibitors of the hepatitis C virus serine protease within non-structural protein 3. Curr. Pharm. Des. 8:2002;2533-2540.
38. Flint M., Quinn E.R., Levy S. In search of hepatitis C virus receptor(s). Clin. Liver Dis. 5:2001;873-893.
39. Friebe P., Bartenschlager R. Genetic analysis of sequences in the 3′ nontranslated region of hepatitis C virus that are important for RNA replication. J. Virol. 76:2002;5326-5338.
40. Friebe P., Lohmann V., Krieger N., Bartenschlager R. Sequences in the 5′ nontranslated region of hepatitis C virus required for RNA replication. J. Virol. 75:2001;12047-12057.
41. Fried M.W. Side effects of therapy of hepatitis C and their management. Hepatology. 36(Suppl. 1):2002;S237-S244.
42. Gardelli, C., Giuliano, C., Harper, S., Koch, U., Narjes, F., Ontoria, J.M., Poma, M., Ponzi, S., Stansfield, I., Summa, V., 2002. Dihydroxypyrimidine carboxylic acids as viral polymerase inhibitors. Int. Patent Appl. WO 02/06246. Istituto di Ricerche di Biologia Molecolare P. Angeletti, SpA.
43. Grakoui A., McCourt D.W., Wychowski C., Feinstone S.M., Rice C.M. Characterization of the hepatitis C virus-encoded serine proteinase: determination of proteinase-dependent polyprotein cleavage sites. J. Virol. 67:1993a;2832-2843.
44. Grakoui A., McCourt D.W., Wychowski C., Feinstone S.M., Rice C.M. A second hepatitis C virus-encoded proteinase. Proc. Natl. Acad. Sci. U.S.A. 90:1993b;10583-10587.
45. Han W., Hu Z., Jiang X., Decicco C.P. Alpha-ketoamides, alpha-ketoesters and alpha-diketones as HCV NS3 protease inhibitors. Bioorg. Med. Chem. Lett. 10:2000;711-713.
46. Hansen J.L., Long A.M., Schultz S.C. Structure of the RNA-dependent RNA polymerase of poliovirus. Structure. 5:1997;1109-1122.
47. Hashimoto, H., Mizutani, K., Yoshida, A., 2001. Preparation of heterocyclic compounds as remedies for hepatitis C. Int. Patent Appl. WO 01/47883. Japan Tobacco Inc.
48. Hazuda D.J., Felock P., Witmer M., Wolfe A., Stillmock K., Grobler J.A., Espeseth A., Gabryelski L., Schleif W., Blau C., Miller M.D. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science. 287:2000;646-650.
49. Hess G., Arnold W., Meyer zum Buschenfelde K.H. Inhibition of hepatitis-B-virus DNA polymerase by phosphonoformate: studies on its mode of action. J. Med. Virol. 5:1980;309-316.
50. Hijikata M., Kato N., Ootsuyama Y., Nakagawa M., Shimotohno K. Gene mapping of the putative structural region of the hepatitis C virus genome by in vitro processing analysis. Proc. Natl. Acad. Sci. U.S.A. 88:1991;5547-5551.
51. Hijikata M., Mizushima H., Akagi T., Mori S., Kakiuchi N., Kato N., Tanaka T., Kimura K., Shimotohno K. Two distinct proteinase activities required for the processing of a putative nonstructural precursor protein of hepatitis C virus. J. Virol. 67:1993;4665-4675.
52. Hinrichsen, H., Benhamou, Y., Hinrichsen, H., Sentjens, R., Reiser, M., Manns, M.P., Forns, X., Avendano, C., Crönlein, C., 2002. First report on the antiviral efficacy of BILN 2061, a novel oral HCV serine protease inhibitor, in patients with chronic hepatitis C genotype 1. Hepatology 36 (Suppl. 4, Pt. 2), Abst. 866.
53. Hong Z., Cameron C.E., Walker M.P., Castro C., Yao N., Lau J.Y., Zhong W. A novel mechanism to ensure terminal initiation by hepatitis C virus NS5B polymerase. Virology. 285:2001;6-11.
54. Houghton, M., 1996. Hepatitis C viruses. In: Fields, B.N., Knipe, David M., Howley, Peter M. (Eds.), Virology, vol. 1. Lippincott-Raven, Philadelphia, New York, pp. 1035-1058.
55. Huge T., Fehrmann F., Bieck E., Kohara M., Krausslich H.G., Rice C.M., Blum H.E., Moradpour D. The hepatitis C virus nonstructural protein 4B is an integral endoplasmic reticulum membrane protein. Virology. 284:2001;70-81.
56. Ilan E., Arazi J., Nussbaum O., Zauberman A., Eren R., Lubin I., Neville L., Ben-Moshe O., Kischitzky A., Litchi A., Margalit I., Gopher J., Mounir S., Cai W., Daudi N., Eid A., Jurim O., Czerniak A., Galun E., Dagan S. The hepatitis C virus (HCV)-Trimera mouse: a model for evaluation of agents against HCV. J. Infect. Dis. 185:2002a;153-161.
57. Ilan E., Eren R., Lubin I., Nussbaum O., Zauberman A., Dagan S. The Trimera mouse: a system for generating human monoclonal antibodies and modeling human diseases. Curr. Opin. Mol. Ther. 4:2002b;102-109.
58. Ingallinella P., Altamura S., Bianchi E., Taliani M., Ingenito R., Cortese R., De Francesco R., Steinkuhler C., Pessi A. Potent peptide inhibitors of human hepatitis C virus NS3 protease are obtained by optimizing the cleavage products. Biochemistry. 37:1998;8906-8914.
59. Ingallinella P., Bianchi E., Ingenito R., Koch U., Steinkuhler C., Altamura S., Pessi A. Optimization of the P′-region of peptide inhibitors of hepatitis C virus NS3/4A protease. Biochemistry. 39:2000;12898-12906.
60. Ingallinella P., Fattori D., Altamura S., Steinkuhler C., Koch U., Cicero D., Bazzo R., Cortese R., Bianchi E., Pessi A. Prime site binding inhibitors of a serine protease: NS3/4A of hepatitis C virus. Biochemistry. 41:2002;5483-5492.
61. Ismaili, H.M.A., Moulay, A., Cheng, Y.-X., Lavallee, J.-F., Siddiqui, A., Storer, R., 2002. Method for the treatment or prevention of flavivirus infections using nucleosides analogues. Int. Patent Appl. WO 01/60315. Biochem Pharma, Inc.
62. Ivashkina N., Wolk B., Lohmann V., Bartenschlager R., Blum H.E., Penin F., Moradpour D. The hepatitis C virus RNA-dependent RNA polymerase membrane insertion sequence is a transmembrane segment. J. Virol. 76:2002;13088-13093.
63. Kato N., Hijikata M., Ootsuyama Y., Nakagawa M., Ohkoshi S., Sugimura T., Shimotohno K. Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. Proc. Natl. Acad. Sci. U.S.A. 87:1990;9524-9528.
64. Kenny-Walsh E. The natural history of hepatitis C virus infection. Clin. Liver Dis. 5:2001;969-977.
65. Kim D.W., Gwack Y., Han J.H., Choe J. C-terminal domain of the hepatitis C virus NS3 protein contains an RNA helicase activity. Biochem. Biophys. Res. Commun. 215:1995;160-166.
66. Kim J.L., Morgenstern K.A., Lin C., Fox T., Dwyer M.D., Landro J.A., Chambers S.P., Markland W., Lepre C.A., O'Malley E.T., Harbeson S.L., Rice C.M., Murcko M.A., Caron P.R., Thomson J.A. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell. 87:1996;343-355.
67. Kim S.Y., Park K.W., Lee Y.J., Back S.H., Goo J.H., Park O.K., Jang S.K., Park W.J. In vivo determination of substrate specificity of hepatitis C virus NS3 protease: genetic assay for site-specific proteolysis. Anal. Biochem. 284:2000;42-48.
68. Koch U., Biasiol G., Brunetti M., Fattori D., Pallaoro M., Steinkuhler C. Role of charged residues in the catalytic mechanism of hepatitis C virus NS3 protease: electrostatic precollision guidance and transition-state stabilization. Biochemistry. 40:2001;631-640.
69. Kolykhalov A.A., Agapov E.V., Rice C.M. Specificity of the hepatitis C virus NS3 serine protease: effects of substitutions at the 3/4A, 4A/4B, 4B/5A, and 5A/5B cleavage sites on polyprotein processing. J. Virol. 68:1994;7525-7533.
70. Kolykhalov A.A., Feinstone S.M., Rice C.M. Identification of a highly conserved sequence element at the 3′ terminus of hepatitis C virus genome RNA. J. Virol. 70:1996;3363-3371.
71. Kolykhalov A.A., Agapov E.V., Blight K.J., Mihalik K., Feinstone S.M., Rice C.M. Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA. Science. 277:1997;570-574.
72. Kolykhalov A.A., Mihalik K., Feinstone S.M., Rice C.M. Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3′ nontranslated region are essential for virus replication in vivo. J. Virol. 74:2000;2046-2051.
73. Krieger N., Lohmann V., Bartenschlager R. Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations. J. Virol. 75:2001;4614-4624.
74. Kukolj, G., McKercher, G., Bernier, L., 2002. HCV polymerase inhibitors assay. Int. Patent Appl. WO 02/070739. Boehringer Ingelhein (Canada) Ltd.
75. Lamarre, D., Bailey, M., Bolger, G., Cameron, D., Cartier, M., Faucher, A.M., Goudreau, N., Kukolj, G., Lagace, L., Pause, A., Rancourt, J., Thibeault, D., Tsantrizos, Y.S., Llinas-Brunet, M., 2002. The discovery of BILN 2061 - an orally bioavailable small molecule inhibitor of the HCV serine protease and a promising target for antiviral treatment of hepatitis C. Hepatology 36 (Suppl. 4, Pt.2), Abst. 464.
76. Landro J.A., Raybuck S.A., Luong Y.P., O'Malley E.T., Harbeson S.L., Morgenstern K.A., Rao G., Livingston D.J. Mechanistic role of an NS4A peptide cofactor with the truncated NS3 protease of hepatitis C virus: elucidation of the NS4A stimulatory effect via kinetic analysis and inhibitor mapping. Biochemistry. 36:1997;9340-9348.
77. Lau J.Y., Tam R.C., Liang T.J., Hong Z. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology. 35:2002;1002-1009.
78. Laurila M.R., Makeyev E.V., Bamford D.H. Bacteriophage phi 6 RNA-dependent RNA polymerase: molecular details of initiating nucleic acid synthesis without primer. J. Biol. Chem. 277:2002;17117-17124.
79. Lesburg C.A., Cable M.B., Ferrari E., Hong Z., Mannarino A.F., Weber P.C. Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nat. Struct. Biol. 6:1999;937-943.
80. Lin C., Lindenbach B.D., Pragai B.M., McCourt D.W., Rice C.M. Processing in the hepatitis C virus E2-NS2 region: identification of p7 and two distinct E2-specific products with different C termini. J. Virol. 68:1994;5063-5073.
81. Lin C., Thomson J.A., Rice C.M. A central region in the hepatitis C virus NS4A protein allows formation of an active NS3-NS4A serine proteinase complex in vivo and in vitro. J. Virol. 69:1995;4373-4380.
82. Lipinski C.A., Lombardo F., Dominy B.W., Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46:2001;3-26.
83. Llinas-Brunet M., Bailey M., Deziel R., Fazal G., Gorys V., Goulet S., Halmos T., Maurice R., Poirier M., Poupart M.A., Rancourt J., Thibeault D., Wernic D., Lamarre D. Studies on the C-terminal of hexapeptide inhibitors of the hepatitis C virus serine protease. Bioorg. Med. Chem. Lett. 8:1998a;2719-2724.
84. Llinas-Brunet M., Bailey M., Fazal G., Goulet S., Halmos T., Laplante S., Maurice R., Poirier M., Poupart M.A., Thibeault D., Wernic D., Lamarre D. Peptide-based inhibitors of the hepatitis C virus serine protease. Bioorg. Med. Chem. Lett. 8:1998b;1713-1718.
85. Llinas-Brunet M., Bailey M., Fazal G., Ghiro E., Gorys V., Goulet S., Halmos T., Maurice R., Poirier M., Poupart M.A., Rancourt J., Thibeault D., Wernic D., Lamarre D. Highly potent and selective peptide-based inhibitors of the hepatitis C virus serine protease: towards smaller inhibitors. Bioorg. Med. Chem. Lett. 10:2000a;2267-2670.
86. Llinas-Brunet, M., Bailey, M.D., Cameron, D., Faucher, A.M., Ghiro, E., Goudreau, N., Halmos, T., Poupart, M.A., Rancourt, J., Tsantrizos, Y.S., Wernic, D.M., Simoneau, B., 2000b. Hepatitis C inhibitor tri-peptides. Int. Patent Appl. WO 00/09543. Boehringer Ingelheim (Canada) Ltd.
87. Lohmann V., Korner F., Herian U., Bartenschlager R. Biochemical properties of hepatitis C virus NS5B RNA-dependent RNA polymerase and identification of amino acid sequence motifs essential for enzymatic activity. J. Virol. 71:1997;8416-8428.
88. Lohmann V., Roos A., Korner F., Koch J.O., Bartenschlager R. Biochemical and kinetic analyses of NS5B RNA-dependent RNA polymerase of the hepatitis C virus. Virology. 249:1998;108-118.
89. Lohmann V., Korner F., Koch J., Herian U., Theilmann L., Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science. 285:1999;110-113.
90. Love R.A., Parge H.E., Wickersham J.A., Hostomsky Z., Habuka N., Moomaw E.W., Adachi T., Hostomska Z. The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site. Cell. 87:1996;331-342.
91. Lu W., Apostol I., Qasim M.A., Warne N., Wynn R., Zhang W.L., Anderson S., Chiang Y.W., Ogin E., Rothberg I., Ryan K., Laskowski M. Jr. Binding of amino acid side chains to S1 cavities of serine proteinases. J. Mol. Biol. 266:1997;441-461.
92. Luo G., Hamatake R.K., Mathis D.M., Racela J., Rigat K.L., Lemm J., Colonno R.J. De novo initiation of RNA synthesis by the RNA-dependent RNA polymerase (NS5B) of hepatitis C virus. J. Virol. 74:2000;851-863.
93. Maag D., Castro C., Hong Z., Cameron C.E. Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin. J. Biol. Chem. 276:2001;46094-46098.
94. McCoy M.A., Senior M.M., Gesell J.J., Ramanathan L., Wyss D.F. Solution structure and dynamics of the single-chain hepatitis C virus NS3 protease NS4A cofactor complex. J. Mol. Biol. 305:2001;1099-1110.
95. McHutchison J.G., Patel K. Future therapy of hepatitis C. Hepatology. 36(Suppl. 1):2002;S245-S252.
96. Mercer D.F., Schiller D.E., Elliott J.F., Douglas D.N., Hao C., Rinfret A., Addison W.R., Fischer K.P., Churchill T.A., Lakey J.R., Tyrrell D.L., Kneteman N.M. Hepatitis C virus replication in mice with chimeric human livers. Nat. Med. 7:2001;927-933.
97. Narjes F., Brunetti M., Colarusso S., Gerlach B., Koch U., Biasiol G., Fattori D., De Francesco R., Matassa V.G., Steinkuhler C. Alpha-ketoacids are potent slow binding inhibitors of the hepatitis C virus NS3 protease. Biochemistry. 39:2000;1849-1861.
98. Narjes F., Koehler K.F., Koch U., Gerlach B., Colarusso S., Steinkuhler C., Brunetti M., Altamura S., De Francesco R., Matassa V.G. A designed P(1) cysteine mimetic for covalent and non-covalent inhibitors of HCV NS3 protease. Bioorg. Med. Chem. Lett. 12:2002a;701-704.
99. Narjes, H., Yong, C.L., Steinmann, G., 2002b. Tolerability and pharmacokinetics of BILN 2061, a novel HCV serine protease inhibitor, after oral single doses of 5 to 2400 mg in healthy male subjects. Hepatology 36 (Suppl. 4, Pt.2), Abst. 800.
100. Ng K.K., Cherney M.M., Vazquez A.L., Machin A., Alonso J.M., Parra F., James M.N. Crystal structures of active and inactive conformations of a caliciviral RNA-dependent RNA polymerase. J. Biol. Chem. 277:2002;1381-1387.
101. Nizi E., Koch U., Ponzi S., Matassa V.G., Gardelli C. Capped dipeptide alpha-ketoacid inhibitors of the HCV NS3 protease. Bioorg. Med. Chem. Lett. 12:2002;3325-3328.
102. Pacini L., Vitelli A., Filocamo G., Bartholomew L., Brunetti M., Tramontano A., Steinkuhler C., Migliaccio G. In vivo selection of protease cleavage sites by using chimeric Sindbis virus libraries. J. Virol. 74:2000;10563-10570.
103. Paul A.V., van Boom J.H., Filippov D., Wimmer E. Protein-primed RNA synthesis by purified poliovirus RNA polymerase. Nature. 393:1998;280-284.
104. Pileri P., Uematsu Y., Campagnoli S., Galli G., Falugi F., Petracca R., Weiner A.J., Houghton M., Rosa D., Grandi G., Abrignani S. Binding of hepatitis C virus to CD81. Science. 282:1998;938-941.
105. Pizzi E., Tramontano A., Tomei L., La Monica N., Failla C., Sardana M., Wood T., De Francesco R. Molecular model of the specificity pocket of the hepatitis C virus protease: implications for substrate recognition. Proc. Natl. Acad. Sci. U.S.A. 91:1994;888-892.
106. Priestley E.S., Decicco C.P. 1-Aminocyclopropaneboronic acid: synthesis and incorporation into an inhibitor of hepatitis C virus NS3 protease. Org. Lett. 2:2000;3095-3097.
107. Priestley E., De Lucca I., Ghavimi B., Erickson-Viitanen S., Decicco C. P1 phenethyl peptide boronic acid inhibitors of HCV NS3 protease. Bioorg. Med. Chem. Lett. 12:2002;3199-3202.
108. Rice, C.M., 1996. Flaviviridae, the viruses and their replication. In: Fields, B.N., Knipe, David, M., Howley, Peter, M. (Eds.), Virology, vol. 1. Lippincott-Raven, Philadelphia, New York, pp. 931-959.
109. Rijnbrand R.C., Lemon S.M. Internal ribosome entry site-mediated translation in hepatitis C virus replication. Curr. Top. Microbiol. Immunol. 242:2000;85-116.
110. Rosenberg S. Recent advances in the molecular biology of hepatitis C virus. J. Mol. Biol. 313:2001;451-464.
111. Sanderson P.E. Small, noncovalent serine protease inhibitors. Med. Res. Rev. 19:1999;179-197.
112. Santolini E., Migliaccio G., La Monica N. Biosynthesis and biochemical properties of the hepatitis C virus core protein. J. Virol. 68:1994;3631-3641.
113. Scarselli E., Ansuini H., Cerino R., Roccasecca R.M., Acali S., Filocamo G., Traboni C., Nicosia A., Cortese R., Vitelli A. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J. 21:2002;5017-5025.
114. Schechter I., Berger A. On the size of the active site in proteases. I. Papain. Biochem. Biophys. Res. Commun. 27:1967;157-162.
115. Schmidt-Mende J., Bieck E., Hugle T., Penin F., Rice C.M., Blum H.E., Moradpour D. Determinants for membrane association of the hepatitis C virus RNA-dependent RNA polymerase. J. Biol. Chem. 276:2001;44052-44063.
116. Shim J.H., Larson G., Wu J.Z., Hong Z. Selection of 3′-template bases and initiating nucleotides by hepatitis C virus NS5B RNA-dependent RNA polymerase. J. Virol. 76:2002;7030-7039.
117. Slater M.J., Andrews D.M., Baker G., Bethell S.S., Carey S., Chaignot H., Clarke B., Coomber B., Ellis M., Good A., Gray N., Hardy G., Jones P., Mills G., Robinson E. Design and synthesis of ethyl pyrrolidine-5,5-trans-lactams as inhibitors of hepatitis C virus NS3/4A protease. Bioorg. Med. Chem. Lett. 12:2002;3359-3362.
118. Sommadossi, J.P., Lacolla, P., 2001. Methods and compositions for treating hepatitis C virus. Int. Patent Appl. WO 01/190121. Idenix Pharmaceuticals.
119. Sperandio D., Gangloff A.R., Litvak J., Goldsmith R., Hataye J.M., Wang V.R., Shelton E.J., Elrod K., Janc J.W., Clark J.M., Rice K., Weinheimer S., Yeung K.S., Meanwell N.A., Hernandez D., Staab A.J., Venables B.L., Spencer J.R. Highly potent non-peptidic inhibitors of the HCV NS3/NS4A serine protease. Bioorg. Med. Chem. Lett. 12:2002;3129-3133.
120. Steinkuhler C., Biasiol G., Brunetti M., Urbani A., Koch U., Cortese R., Pessi A., De Francesco R. Product inhibition of the hepatitis C virus NS3 protease. Biochemistry. 37:1998;8899-8905.
121. Steinkuhler, C., Koch, U., De Francesco, R., Pessi, A., 2000. The proteinases encoded by hepatitis C virus as therapeutic target. In: von der Helm, K., Korant, B.D., Cheronis, J.C. (Eds.), Proteases as Targets for Therapy, vol. 140. Springe-Verlag, Berlin Heidelberg, pp. 75-94.
122. Steinkuhler C., Koch U., Narjes F., Matassa V.G. Hepatitis C virus protease inhibitors: current progress and future challenges. Curr. Med. Chem. 8:2001;919-932.
123. Storer, R., 2001. Method for the treatment or prevention of Flaviridae viral infection using nucleoside analogs. Int. Patent Appl. WO 01/32153. Biochem Pharma, Inc.
124. Sundquist B., Oberg B. Phosphonoformate inhibits reverse transcriptase. J. Gen. Virol. 45:1979;273-281.
125. Takamizawa A., Mori C., Fuke I., Manabe S., Murakami S., Fujita J., Onishi E., Andoh T., Yoshida I., Okayama H. Structure and organization of the hepatitis C virus genome isolated from human carriers. J. Virol. 65:1991;1105-1113.
126. Tan S.L., Katze M.G. How hepatitis C virus counteracts the interferon response: the jury is still out on NS5A. Virology. 284:2001;1-12.
127. Tanaka T., Kato N., Cho M.J., Shimotohno K. A novel sequence found at the 3′ terminus of hepatitis C virus genome. Biochem. Biophys. Res. Commun. 215:1995;744-749.
128. Tomassini J., Selnick H., Davies M.E., Armstrong M.E., Baldwin J., Bourgeois M., Hastings J., Hazuda D., Lewis J., McClements W.et al. Inhibition of cap (m7GpppXm)-dependent endonuclease of influenza virus by 4-substituted 2,4-dioxobutanoic acid compounds. Antimicrob. Agents Chemother. 38:1994;2827-2837.
129. Tomei L., Failla C., Santolini E., De Francesco R., La Monica N. NS3 is a serine protease required for processing of hepatitis C virus polyprotein. J. Virol. 67:1993;4017-4026.
130. Tomei L., Vitale R.L., Incitti I., Serafini S., Altamura S., Vitelli A., De Francesco R. Biochemical characterization of a hepatitis C virus RNA-dependent RNA polymerase mutant lacking the C-terminal hydrophobic sequence. J. Gen. Virol. 81:2000;759-767.
131. Tsukiyama-Kohara K., Iizuka N., Kohara M., Nomoto A. Internal ribosome entry site within hepatitis C virus RNA. J. Virol. 66:1992;1476-1483.
132. Urbani A., Bianchi E., Narjes F., Tramontano A., De Francesco R., Steinkuhler C., Pessi A. Substrate specificity of the hepatitis C virus serine protease NS3. J. Biol. Chem. 272:1997;9204-9209.
133. Urbani A., Bazzo R., Nardi M.C., Cicero D.O., De Francesco R., Steinkuhler C., Barbato G. The metal binding site of the hepatitis C virus NS3 protease. A spectroscopic investigation. J. Biol. Chem. 273:1998;18760-18769.
134. Walewski J.L., Keller T.R., Stump D.D., Branch A.D. Evidence for a new hepatitis C virus antigen encoded in an overlapping reading frame. RNA. 7:2001;710-721.
135. Wasley A., Alter M.J. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin. Liver Dis. 20:2000;1-16.
136. Watson J. Prospects for hepatitis C virus therapeutics: levovirin and viramidine as improved derivatives of ribavirin. Curr. Opin. Invest. Drugs. 3:2002;680-683.
137. Xu Z., Choi J., Yen T.S., Lu W., Strohecker A., Govindarajan S., Chien D., Selby M.J., Ou J. Synthesis of a novel hepatitis C virus protein by ribosomal frameshift. EMBO J. 20:2001;3840-3848.
138. Yan Y., Li Y., Munshi S., Sardana V., Cole J.L., Sardana M., Steinkuehler C., Tomei L., De Francesco R., Kuo L.C., Chen Z. Complex of NS3 protease and NS4A peptide of BK strain hepatitis C virus: a 2.2 A resolution structure in a hexagonal crystal form. Protein Sci. 7:1998;837-847.
139. Yao N., Reichert P., Taremi S.S., Prosise W.W., Weber P.C. Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease-helicase. Struct. Fold. Des. 7:1999;1353-1363.
140. Yeung K.S., Meanwell N.A., Qiu Z., Hernandez D., Zhang S., McPhee F., Weinheimer S., Clark J.M., Janc J.W. Structure-activity relationship studies of a bisbenzimidazole-based, Zn(2+)-dependent inhibitor of HCV NS3 serine protease. Bioorg. Med. Chem. Lett. 11:2001;2355-2359.
141. Zhang R., Durkin J., Windsor W.T., McNemar C., Ramanathan L., Le H.V. Probing the substrate specificity of hepatitis C virus NS3 serine protease by using synthetic peptides. J. Virol. 71:1997;6208-6213.
142. Zhang R., Durkin J.P., Windsor W.T. Azapeptides as inhibitors of the hepatitis C virus NS3 serine protease. Bioorg. Med. Chem. Lett. 12:2002;1005-1008.
143. Zhong W., Uss A.S., Ferrari E., Lau J.Y., Hong Z. De novo initiation of RNA synthesis by hepatitis C virus nonstructural protein 5B polymerase. J. Virol. 74:2000;2017-2022.